| Primary Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection for Neovascular Age-related Macular Degeneration. |
|
Young Ju Lew, Hae Jin Park, Tae Gon Lee, Dong Won Lee, Sung Won Cho, Jae Heung Lee |
1MyungGok Eye Research Institute, Konyang University, Kim's Eye Hospital, Seoul, Korea.
2Department of Ophthalmology, College of Medicine, Konyang University, Deajeon, Korea. idoc@kimeye.com |
| 신생혈관성 나이관련황반변성에서 베바시주맙 주입과 광역학요법을 병합한 일차치료 효과 |
|
유영주1ㆍ박혜진1ㆍ이태곤2ㆍ이동원1ㆍ조성원1ㆍ이재흥1 |
|
MyungGok Eye Research Institute, Konyang University, Kim’s Eye Hospital1, Seoul, Korea, Department of Ophthalmology, College of Medicine, Konyang University2, Deajeon, Korea |
|
|
| Abstract |
PURPOSE
To investigate the efficacy of the combined treatment of photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in patients with neovascular age-related macular degeneration. METHODS: Forty-five eyes received a single session of PDT following three intravitreal bevacizumab (1.25 mg) injections at six-week intervals (IVB+PDT group). Twenty-seven eyes received three intravitreal bevacizuamb (1.25 mg) injections only at six-week intervals (IVB group). RESULTS: After the six months of follow up, the mean BCVA (LogMAR) changed significantly from 0.62+/-0.34 to 0.56+/-0.33 in the IVB group (p=0.03) and from 0.61+/-0.33 to 0.48+/-0.21 in the IVB+PDT group (p=0.001). The mean BCVA was more improved in the IVB+PDT group (p=0.049). The mean CMT changes were significant in both groups immediately after treatment, but there was no significant difference at six months between the two groups. Ten eyes (37.0%) in the IVB group and 12 eyes (26.7%) in the IVB+PDT group required retreatments during the six months of follow-up (p=0.02). CONCLUSIONS: Significant improvement in visual acuity and reduction in central macular thickness over a six-months period were observed in both groups. The mean visual acuity was significantly better and the rate of reinjections after the initial treatment schedule was lower in the IVB+PDT group. |
| Key Words:
Age-related macular degeneration;Bevacizumab;Choroidal neovascularization;Photodynamic therapy |
|
PDF Links
Full text via DOI
Download Citation
